文献速递头颈部肿瘤放疗

甲状腺V40是鼻咽癌调强放疗后亚临床甲状腺功能减退的良好预测指标:一项随机临床试验

Thyroid V40 is a good predictor for subclinical hypothyroidism in patients with nasopharyngeal carcinoma after intensity modulated radiation therapy: a randomized clinical trial.
PubMed 文献 · Radiat Oncol · 2023-08-25

该单中心1:1随机临床试验于2018年3月至2022年9月在福建省立医院纳入92例鼻咽癌患者,比较甲状腺V40≤85%剂量约束与无限制对亚临床甲状腺功能减退的影响,中位随访34个月,剂量约束组亚临床甲减风险低于无限制组(HR=0.408,95%CI 0.184-0.904)。

要点

  • 甲状腺V40≤85%剂量约束组亚临床甲减发生率与无限制组差异有统计学意义(P=0.023)。
  • 剂量约束组亚临床甲减风险低于无限制组(P=0.022;HR=0.408,95%CI 0.184-0.904)。
  • 多因素校正后甲状腺剂量约束对亚临床甲减呈保护效应(HRadjusted=0.361,95%CI 0.155-0.841)。

核心结论

  • V40≤85%可作为调强放疗计划中的有效剂量约束以预防放射性亚临床甲状腺功能减退。

研究设计与样本

  • 单中心1:1随机临床试验,2018年3月至2022年9月在福建省立医院开展,纳入92例临床鼻咽癌患者。
  • 所有患者接受调强放疗,随机分为诱导化疗后同步化疗-调强放疗或单纯同步化疗-调强放疗。
  • 甲状腺剂量约束定义为V40≤85%,主要结局为亚临床甲状腺功能减退,中位随访34个月。

主要发现

  • 甲状腺剂量约束组与无限制组亚临床甲减发生率差异有统计学意义(P=0.023)。
  • 甲状腺剂量约束组亚临床甲减风险低于无限制组(P=0.022)。
  • 单因素和多因素Cox回归分析显示甲状腺剂量约束对亚临床甲减呈保护效应(HR=0.408,95%CI 0.184-0.904;校正HR=0.361,95%CI 0.155-0.841)。

关键数值与推荐

  • 甲状腺剂量约束定义为V40≤85%。
  • 主要结局为亚临床甲状腺功能减退。

临床怎么用

  • 原文结论认为V40≤85%可作为调强放疗计划中的有效剂量约束以预防放射性亚临床甲状腺功能减退。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypothyroidism (HT) and subclinical HT after radiotherapy is frequent in nasopharyngeal carcinoma (NPC) patients, results in negative impact on patients' quality of life. The percentage of thyroid volume receiving more than 40 Gy (V40) ≤ 85% was reported to be a useful dose constraint to adopt during intensity-modulated radiation therapy (IMRT) planning. This study aims to verify whether V40 ≤ 85% can be used as an effective dose constraint in IMRT planning in a randomized clinical trial. METHODS: This single-center 1:1 randomized clinical trial was conducted in Fujian province hospital between March 2018 and September 2022. All patients were treated with IMRT and randomized to induction chemo followed by concurrent chemo-IMRT or concurrent chemo-IMRT alone. Ninety-two clinically NPC patients were included in this study. The thyroid function tests were performed for all patients before and after radiation at regular intervals. Thyroid dose-constraint was defined as V40 ≤ 85%. The primary outcome in this study was subclinical HT. RESULTS: Median follow up was 34 months. Significant difference in the incidence of subclinical HT between the thyroid dose-constraint group and unrestricted group was observed (P = 0.023). The risk of subclinical HT in the thyroid dose-constraint group was lower than that in the unrestricted group (P = 0.022). Univariate and multivariate cox regression analysis indicated that thyroid dose-constraint was a protective effect of subclinical HT (HR = 0.408, 95% CI 0.184-0.904; HRadjusted = 0.361, 95% CI 0.155-0.841). CONCLUSION: V40 ≤ 85% can be used as an effective dose constraint in IMRT planning to prevent radiation-induced subclinical HT.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Xu Y, Peng H, Su G, et al. Thyroid V40 is a good predictor for subclinical hypothyroidism in patients with nasopharyngeal carcinoma after intensity modulated radiation therapy: a randomized clinical trial. Radiat Oncol. 2023. PMID: 37626342. doi:10.1186/s13014-023-02329-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。